Igor Odintsov

472 total citations
24 papers, 235 citations indexed

About

Igor Odintsov is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Igor Odintsov has authored 24 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Igor Odintsov's work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (8 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Igor Odintsov is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (8 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Igor Odintsov collaborates with scholars based in United States, Canada and Japan. Igor Odintsov's co-authors include Marc Ladanyi, Romel Somwar, Elisa de Stanchina, Inna Khodos, Marissa S. Mattar, Lynette M. Sholl, Alexander Drilon, Michael Offin, Morana Vojnic and William W. Lockwood and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Igor Odintsov

21 papers receiving 229 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Igor Odintsov United States 9 146 123 94 52 29 24 235
Lukas Delasos United States 8 157 1.1× 121 1.0× 64 0.7× 62 1.2× 23 0.8× 20 230
Vanessa Chaire France 11 171 1.2× 181 1.5× 137 1.5× 55 1.1× 17 0.6× 19 315
Donna C. Ferguson United States 7 91 0.6× 65 0.5× 91 1.0× 50 1.0× 25 0.9× 15 220
Joanna Vitfell-Rasmussen United Kingdom 5 94 0.6× 134 1.1× 165 1.8× 39 0.8× 78 2.7× 6 337
Aurélie Maran-Gonzalez France 7 88 0.6× 165 1.3× 54 0.6× 119 2.3× 46 1.6× 16 258
Sofia Westbom-Fremer Sweden 7 99 0.7× 187 1.5× 56 0.6× 56 1.1× 39 1.3× 12 299
Nobuhiko Nishijima Japan 8 143 1.0× 110 0.9× 133 1.4× 79 1.5× 9 0.3× 15 302
Audrey Monneur France 10 78 0.5× 138 1.1× 59 0.6× 97 1.9× 10 0.3× 20 251
Morana Vojnic United States 7 165 1.1× 132 1.1× 129 1.4× 45 0.9× 21 0.7× 24 276
Takayuki Sumiyoshi Japan 11 247 1.7× 90 0.7× 124 1.3× 145 2.8× 30 1.0× 41 351

Countries citing papers authored by Igor Odintsov

Since Specialization
Citations

This map shows the geographic impact of Igor Odintsov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor Odintsov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor Odintsov more than expected).

Fields of papers citing papers by Igor Odintsov

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Igor Odintsov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor Odintsov. The network helps show where Igor Odintsov may publish in the future.

Co-authorship network of co-authors of Igor Odintsov

This figure shows the co-authorship network connecting the top 25 collaborators of Igor Odintsov. A scholar is included among the top collaborators of Igor Odintsov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor Odintsov. Igor Odintsov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Odintsov, Igor, Mark M. Hammer, Biagio Ricciuti, et al.. (2025). The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes. Journal of Thoracic Oncology. 21(3). 103501–103501.
2.
Odintsov, Igor, Federica Pecci, Mihaela Aldea, et al.. (2025). Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report. JCO Precision Oncology. 9(9). e2500184–e2500184. 1 indexed citations
3.
Odintsov, Igor, David Papke, Suzanne George, et al.. (2025). Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations, and a High Burden of Germline POT1 Alterations. Clinical Cancer Research. 31(6). 1091–1102.
4.
Febres‐Aldana, Christopher A., Zebing Liu, Raymond G. Dematteo, et al.. (2024). HER2 Antibody–Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor. Clinical Cancer Research. 30(20). 4701–4713. 6 indexed citations
5.
Elkrief, Arielle, Igor Odintsov, Roger S. Smith, et al.. (2024). Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification. JCO Precision Oncology. 8(8). e2400241–e2400241. 3 indexed citations
6.
Miyazaki, Isao, et al.. (2024). Preclinical evaluation of targeted therapies for central nervous system metastases. Disease Models & Mechanisms. 17(9). 3 indexed citations
7.
O’Connor, Marie, Ron C.J. Schackmann, Igor Odintsov, et al.. (2024). Abstract 1903: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expression. Cancer Research. 84(6_Supplement). 1903–1903. 1 indexed citations
8.
Odintsov, Igor, Karen Fritchie, Yin P. Hung, et al.. (2024). Clear Cell Stromal Tumor of the Lung: Clinicopathologic, Immunohistochemical, and Molecular Characterization of Eight Cases. Modern Pathology. 38(1). 100632–100632. 5 indexed citations
9.
Udagawa, Hibiki, Monique B. Nilsson, Jacqulyne Robichaux, et al.. (2023). HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. Journal of Thoracic Oncology. 19(1). 106–118. 9 indexed citations
10.
Odintsov, Igor, et al.. (2023). Abstract A036: A subset of lung adenocarcinomas defined by high-level ERBB2 amplification is vulnerable to HER2-targeted therapy. Molecular Cancer Therapeutics. 22(12_Supplement). A036–A036.
11.
Odintsov, Igor & Lynette M. Sholl. (2023). Prognostic and predictive biomarkers in non-small cell lung carcinoma. Pathology. 56(2). 192–204. 9 indexed citations
12.
Odintsov, Igor, Maisam Makarem, Mizuki Nishino, et al.. (2023). Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. Journal of Thoracic Oncology. 19(5). 732–748. 11 indexed citations
13.
Elkrief, Arielle, Igor Odintsov, Vladimir Markov, et al.. (2023). Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification. Journal of Thoracic Oncology. 18(9). 1165–1183. 13 indexed citations
14.
Odintsov, Igor, Zebing Liu, Lukas Delasos, et al.. (2021). The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clinical Cancer Research. 27(11). 3154–3166. 31 indexed citations
15.
Odintsov, Igor, Marissa S. Mattar, Michael Offin, et al.. (2021). Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. Journal of Thoracic Oncology. 16(7). 1149–1165. 21 indexed citations
16.
Odintsov, Igor, Kota Ishizawa, Lukas Delasos, et al.. (2021). Abstract P233: TAS0953/HM06 is effective in preclinical models of diverse tumor types driven by RET alterations. Molecular Cancer Therapeutics. 20(12_Supplement). P233–P233. 5 indexed citations
17.
Odintsov, Igor, et al.. (2021). Abstract 935: Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions. Cancer Research. 81(13_Supplement). 935–935. 1 indexed citations
18.
Ogura, Koichi, Romel Somwar, Julija Hmeljak, et al.. (2020). Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor. Clinical Cancer Research. 27(4). 1184–1194. 24 indexed citations
19.
Somwar, Romel, Nicolle E. Hofmann, Bryan D. Smith, et al.. (2020). NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications Biology. 3(1). 776–776. 41 indexed citations
20.
Suzawa, Ken, Michael Offin, Adam J. Schoenfeld, et al.. (2019). Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung Cancer. JCO Precision Oncology. 1–8. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lukas Delasos Breakdown of academic impact, for papers by Vanessa Chaire Breakdown of academic impact, for papers by Donna C. Ferguson Breakdown of academic impact, for papers by Joanna Vitfell-Rasmussen Breakdown of academic impact, for papers by Aurélie Maran-Gonzalez Breakdown of academic impact, for papers by Sofia Westbom-Fremer Breakdown of academic impact, for papers by Nobuhiko Nishijima Breakdown of academic impact, for papers by Audrey Monneur Breakdown of academic impact, for papers by Morana Vojnic Breakdown of academic impact, for papers by Takayuki Sumiyoshi
Rankless by CCL
2026